When does semaglutide’s patent protection end?
You generally can’t give one single “end date” for all semaglutide products, because “patent end” depends on the specific patent(s) covering each drug and each jurisdiction. Different patents can expire at different times, and some may be extended with regulatory exclusivities or litigation.
Which patents people usually mean for semaglutide (Ozempic/Rybelsus/Wegovy)?
Semaglutide is sold under multiple brands, and each one is tied to its own mix of patent families and exclusivities. That means the last protection date can differ between:
- Ozempic (injectable)
- Rybelsus (oral)
- Wegovy (weight-loss indication)
To answer accurately, you need the country (US, EU, UK, etc.) and the exact patent/patent family number or the specific product/indication.
How do you find the exact “end date” for your country and brand?
Look up patent status using:
- The relevant country’s patent database (for the exact patent family)
- The brand’s “orange book” style listings (US) or equivalent national registers
- Any listed patent numbers tied to the drug submission and indication
This tells you the statutory expiry date and whether there are extensions (like pediatric exclusivity in the US, where applicable).
Can generic or biosimilar semaglutide enter before patents expire?
Usually not for the same exact protected formulations/uses as long as relevant patents and exclusivities are still in force. However, market entry timelines can move based on:
- Whether a product challenges specific patents successfully
- Whether the challenger design works around the protected claims
- Whether regulatory exclusivity (separate from patents) blocks approval even if a patent is later
What I need to give you a specific end date
Reply with:
1) your country (e.g., US, UK, EU), and
2) which semaglutide product/indication you mean (Ozempic, Rybelsus, Wegovy; and if weight loss vs diabetes matters).
Then I can tell you the most likely “last patent expiry/exclusivity” date for that exact context.